Biosimilars in hematology and oncology /

Cornes, Paul (Oncologist),

Biosimilars in hematology and oncology / [e-book] - 1 online resource (128 pages) : illustrations (black and white, and colour). - Fast facts . - Fast facts. .

Also issued in print: 2020.

Includes bibliographical references and index.

Biologics have revolutionised - and are revolutionising - the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars - particularly in curative cancer treatment, where they are relatively recent therapeutic options. 'Biosimilars in Hematology and Oncology' provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients.

Specialized.

9781912776221 (PDF ebook) : No price No price


Pharmaceutical biotechnology.
Hematology.
Oncology.
Technology, Pharmaceutical.
Hematology.
Medical Oncology.

QV 4
London Health Libraries Koha Consortium privacy notice